CD4+and CD25+T-cell response to short-time interferon-beta therapy on IL10, IL23A and FOXP3 genes in multiple sclerosis patients

Gezmis H., Doran T., Mayda Domac F., YÜCEL D., Karaci R., Kirac D.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.75, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 75
  • Publication Date: 2021
  • Doi Number: 10.1111/ijcp.14238
  • Journal Name: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

Aim of the Study Interferon-beta (IFN-beta), multiple sclerosis (MS) drug for years, does not have therapeutic effects on each patient. Yet, a considerable portion has experienced no therapeutic response to IFN-beta. Therefore, it is necessary to determine disease-specific biomarkers that affect drug response. Here, we aimed to determine the effects of interleukin 10 (IL10) and 23 (IL23A), as well as forkhead box P3 (FOXP3) genes on MS after IFN-beta therapy.